Rejuveron appoints anti-aging pioneer to Scientific Advisory Board

Swiss biotech Rejuveron announces the appointment of biomedical gerontologist, Dr Aubrey de Grey.

Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, has announced the appointment of biomedical gerontologist, Dr Aubrey de Grey, to its Scientific Advisory Board (SAB).

De Grey joins Rejuveron’s current SAB members Professor Lee Rubin (Harvard Stem Cell Institute) and Professor Hideyuki Okano (Dean, Keio University School of Medicine).

De Grey is renowned for his work on using technological approaches to solve age-related health conditions. He is the Chief Science Officer of the non-profit SENS Research Foundation, editor-in-chief of the academic journal Rejuvenation Research and a member of Longevity.Technology‘s own Advisory Panel.

Rejuveron is building a new incubator lab space at the Bio-Technopark in Schlieren (Zürich) to provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Matthias Steger, CEO of Rejuveron said: “Aubrey De Grey’s expertise will bring an extra dimension to Rejuveron’s research into slowing down or reversing the aging process. His input will be invaluable for our incubator model, which aims to attract the best scientific brains in the field of aging, and support them in bringing their ideas to life.”

Aubrey de Grey said: “Rejuveron’s strategy fits perfectly with my own long-held ambitions of helping humans to live longer, healthier lives. Now that the biology of aging has transformed unequivocally from a basic science field to a biomedical one, and the private sector involvement is growing exponentially, I am delighted and honoured to be able to contribute to the efforts of such a key player in the sector.”